Skip to main content
SpringerLink
Log in

Analgetika

  • Chapter
  • First Online:
Arzneiverordnungs-Report 2020

  • 3126 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 69.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 89.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Literatur

  • Andrade S, Bartels DB, Lange R, Sandford L, Gurwitz J (2016) Safety of metamizole: a systematic review of the literature. J Clin Pharm Ther 41:459–477

    Article  CAS  PubMed  Google Scholar 

  • Arzneimittelkommission der deutschen Ärzteschaft (1986) Bundesgesundheitsamt schränkt Anwendungsgebiet von Metamizol-haltigen Monopräparaten ein. Dtsch Arztebl 83:3267

    Google Scholar 

  • Arzneimittelkommission der deutschen Ärzteschaft (2007) Empfehlungen zur Therapie von Tumorschmerzen. AVP-Sonderheft Therapieempfehlungen, 3. Auflage. http://www.akdae.de/35/10/66-Tumorschmerzen-2007-3Auflage.pdf

  • Arzneimittelkommission der deutschen Ärzteschaft (2012) Die unkritische Anwendung von Fentanylpflastern erhöht das Risiko für schwerwiegende Nebenwirkungen (UAW-News International). Dtsch Arztebl 109:A724–A725

    Google Scholar 

  • Bao YJ, Hou W, Kong XY, Yang L, Xia J, Hua BJ, Knaggs R (2016) Hydromorphone for cancer pain. Cochrane Database Syst Rev 10:CD11108

    PubMed  Google Scholar 

  • Bohnert AS, Valenstein M, Bair MJ, Ganoczy D, McCarthy JF, Ilgen MA, Blow FC (2011) Association between opioid prescribing patterns and opioid overdose-related deaths. JAMA 305:1315–1321

    Article  CAS  PubMed  Google Scholar 

  • Bornemann-Cimenti H, Wejbora M, Szilagyi I, Sandner-Kiesling A (2013) Fentanyl zur Behandlung von tumorbedingten Durchbruchschmerzen. Dtsch Arztebl 110:271–277

    Google Scholar 

  • Boscarino JA, Rukstalis M, Hoffmann SN, Han JJ, Erlich PM, Gerhard GS, Steward WF (2010) Risk factors for drug dependence among out-patients on opioid therapy in a large US health-care system. Addiction 105:1776–1782

    Article  PubMed  Google Scholar 

  • Brat GA, Agniel D, Beam A, Yorkgitis B, Bickel M, Homer M, Fox KP, Knecht DB, McMahill-Walraven CN, Palmer N, Kohane I (2018) Postsurgical prescriptions for opioid naïve patients and association with overdose and misuse: retrospective cohort study. Brit Med J 360:j5790

    Article  PubMed  PubMed Central  Google Scholar 

  • Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF) (2017) Nationale VersorgungsLeitlinie Nicht-spezifischer Kreuzschmerz – Langfassung, 2. Aufl. https://doi.org/10.6101/AZQ/000353 (Version 1, www.kreuzschmerz.versorgungsleitlinien.de)

    Book  Google Scholar 

  • Busse JW, Wang L, Kamaleldin M, Craigie S, Riva JJ, Montoya L, Mulla SM, Lopes LC, Vogel N, Chen E, Kirmayr K, De Oliveira K, Olivieri L, Kaushal A, Chaparro LE, Oyberman I, Agarwal A, Couban R, Tsoi L, Lam T, Vandvik PO, Hsu S, Bala MM, Schandelmaier S, Scheidecker A, Ebrahim S, Ashoorion V, Rehman Y, Hong PJ, Ross S, Johnston BC, Kunz R, Sun X, Buckley N, Sessler DI, Guyatt GH (2018) Opioids for chronic noncancer pain: a systematic review and meta-analysis. JAMA 320:2448–2460

    Article  PubMed  PubMed Central  Google Scholar 

  • Drover DR, Angst MS, Valle M, Ramaswamy B, Naidu S, Stanski DR, Verotta D (2002) Input characteristics and bioavailability after administration of immediate and a new extended-release formulation of hydromorphone in healthy volunteers. Anesthesiology 97:827–836

    Article  CAS  PubMed  Google Scholar 

  • Fallon M, Giusti R, Aielli F, Hoskin P, Rolke R, Sharma M, Ripamonti CI, ESMO Guidelines Committee (2018) Management of cancer pain in adult patients: ESMO Clinical Practice Guidelines. Ann Oncol 29(Suppl 4):iv191–iv166

    Google Scholar 

  • Faria J, Barbosa J, Moreira R, Queirós O, Dinis-Oliveira RJ (2018) Comparative pharmacology and toxicology of tramadol and tapentalol. Eur J Pain 22:827–844

    Article  CAS  PubMed  Google Scholar 

  • Foster B, Twycross R, Mihalyo M, Wilcock A (2013) Buprenorphine. J Pain Symptom Manage 45:939–949

    Google Scholar 

  • Frampton JE (2010) Tapentadol immediate release: a review of its use in the treatment of moderate to severe acute pain. Drugs 70:1719–1743

    Article  CAS  PubMed  Google Scholar 

  • Garbe E, Jobski K, Schmid U (2012) Utilisation of transdermal fentanyl in Germany from 2004 to 2006. Pharmacoepidemiol Drug Saf 21:191–198

    Article  PubMed  Google Scholar 

  • Häuser W, Petzke F, Radburch L (2020) Die US-amerikanische Opioidepidemie bedroht Deutschland. Schmerz 34:1–3

    Article  PubMed  Google Scholar 

  • Healton C, Pack R, Galea S (2019) The opioid crisis, corporate responsibility, and lessons from the tobacco master settlement agreement. JAMA 2019:1. https://doi.org/10.1001/jama.2019.17144

    Article  Google Scholar 

  • Hoffmann F, Bantel C, Jobski K (2020) Agranulocytosis attributed to metamizole: An analysis of spontaneous reports in Eudra Vigilance 1985–2017. Basic Clin Pharmacol Toxicol 126:116–126

    Article  CAS  PubMed  Google Scholar 

  • Kassenärztliche Bundesvereinigung (2012a) Oxycodon/Naloxon. Wirkstoff aktuell Ausgabe 6/2012. http://www.akdae.de/Arzneimitteltherapie/WA/Archiv/Oxycodon-Naloxon.pdf

  • Kassenärztliche Bundesvereinigung (2012b) Tapentadol. Wirkstoff aktuell Ausgabe 3/2012. http://www.akdae.de/Arzneimitteltherapie/WA/Archiv/Tapentadol.pdf

  • Kaye AD, Jones MR, Kaye AM, Ripoll JG, Galan V, Beakley BD, Calixto F, Bolden JL, Urman RD, Manchikanti L (2017) Prescription opioid abuse in chronic pain: an updated review of opioid abuse predictors and strategies to curb opioid abuse: part 1. Pain Phys 20:93–109

    Article  Google Scholar 

  • Langford RM, Knaggs R, Farguhar-Smith P, Dickenson AH (2016) Is tapentalol different from classical opioids? A review of the evidence. Brit J Pain 10:217–221

    Article  Google Scholar 

  • Meissner W, Leyendecker P, Mueller-Lissner S, Nadstawek J, Hopp M, Ruckes C, Wirz S, Fleischer W, Reimer K (2009) A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation. Eur J Pain 13:56–64

    Article  CAS  PubMed  Google Scholar 

  • Oliveira CB, Maher CG, Pinto RZ, Traeger AC, Lin CC, Chenot JF, van Tulder M, Koes BW (2018) Clinical practice guidelines for the management of non-specific low back pain in primary care: an updated overview. Eur Spine J 27:2791–2803

    Article  PubMed  Google Scholar 

  • Reinecke H, Weber C, Lange K, Simon M, Stein C, Sorgatz H (2015) Analgesic efficacy of opioids in chronic pain: recent meta-analyses. Br J Pharmacol 172:324–333

    Google Scholar 

  • Ripamonti C, Fagnoni E, Campa T, Brunelli C, De Conno F (2006) Is the use of transdermal fentanyl inappropriate according to the WHO guidelines and the EAPC recommendations? A study of cancer patients in Italy. Support Care Cancer 14:400–407

    Article  PubMed  Google Scholar 

  • Rosner B, Neicun J, Yang JC, Roman-Urrestarazu A (2019) Opioid prescription patterns in Germany and the global opioid epidemic: Systematic review of available evidence. PLoS ONE 14(8):e221153. https://doi.org/10.1371/journal.pone.0221153

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Schmidt-Hansen M, Bromham N, Taubert M, Arnold S, Hilgart JS (2015) Buprenorphine for treating cancer pain. Cochrane Database Syst Rev 31(3):CD9596. https://doi.org/10.1002/14651858.CD009596.pub4

    Article  Google Scholar 

  • Sommer C, Klose P, Welsch P, Petzke F, Häuser W (2020) Opioids for chronic non-cancer neuropathic pain. An updated systematic review and meta-analysis of efficacy, tolerability and safety in randomized placebo-controlled studies of at least 4 weeks duration. Eur J Pain 24:3–18

    Article  PubMed  Google Scholar 

  • Spithoff S, Leece P, Sullivan F, Persaud N, Belesiotis P, Steiner L (2020) Drivers of the opioid crisis: An appraisal of financial conflicts of interest in clinical practice guideline panels at the peak of opioid prescribing. PLoS ONE 15(1):e227045. https://doi.org/10.1371/journal.pone.0227045

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Straube C, Derry S, Jackson KC, Wiffen PJ, Bell RF, Strassels S, Straube S (2014) Codeine, alone and with paracetamol (acetaminophen), for cancer pain. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD006601.pub4

    Article  PubMed  PubMed Central  Google Scholar 

  • Swarm RA, Paice JA, Anghelescu DL, Are M, Bruce JY, Buga S, Chwistek M, Cleeland C, Craig D, Gafford E, Greenlee H, Hansen E, Kamal AH, Kamdar MM, LeGrand S, Mackey S, McDowell MR, Moryl N, Nabell LM, Nesbit S, BCPS, O’Connor N, Rabow MW, Rickerson E, Shatsky R, Sindt J, Urba SG, Youngwerth JM, Hammond LJ, Gurski LA (2019) Adult Cancer Pain, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 17:977–1007

    Article  CAS  PubMed  Google Scholar 

  • Wiffen PJ, Derry S, Naessens K, Bell RF (2015) Oral tapentalol for cancer pain. Cochrane Database Syst Rev 2015:CD11460

    PubMed Central  Google Scholar 

  • Wiffen PJ, Knaggs R, Derry S, Cole P, Phillips T, Moore RA (2016) Paracetamol (acetaminophen) with or without codeine or dihydrocodeine for neuropathic pain in adults. Cochrane Database Syst Rev 12:CD12227

    PubMed  Google Scholar 

  • Wilcock A (2009) Prolonged-release naloxone can cause systemic opioid withdrawal. Eur J Pain 1001(2009):13

    Google Scholar 

  • World Health Organization (WHO) (1986) Cancer pain relief. World Health Organization Publications, Geneva

    Google Scholar 

  • World Health Organization (WHO) (2018) WHO Guidelines for the pharmacologic and radiotherapeutic management of cancer pain in adults and adolescents. https://www.ncbi.nlm.nih.gov/books/NBK537492/

Download references

Author information

Authors and Affiliations

  1. Institut für Klinische Pharmakologie und Toxikologie, Universitätsklinikum Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Deutschland

    Prof. Dr. med. Rainer H. Böger

  2. Institut für Pharmakologie und Toxikologie der Universität Göttingen, Robert-Koch-Straße 40, 37075, Göttingen, Deutschland

    Prof. Dr. med. Gerhard Schmidt

Authors
  1. Prof. Dr. med. Rainer H. Böger
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prof. Dr. med. Gerhard Schmidt
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rainer H. Böger .

Editor information

Editors and Affiliations

  1. Pharmakologisches Institut, Universität Heidelberg, Heidelberg, Baden-Württemberg, Germany

    Ulrich Schwabe

  2. Arzneimittelkommission der deutschen Ärzteschaft, Berlin, Berlin, Germany

    Wolf-Dieter Ludwig

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Der/die Herausgeber bzw. der/die Autor(en), exklusiv lizenziert durch Springer-Verlag GmbH, DE, ein Teil von Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Böger, R.H., Schmidt, G. (2020). Analgetika. In: Schwabe, U., Ludwig, WD. (eds) Arzneiverordnungs-Report 2020. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-62168-4_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-62168-4_7

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-62167-7

  • Online ISBN: 978-3-662-62168-4

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation